Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES1 | P23141 | 3/20 | 0.36 |
| ▸ | PDE7A | Q13946 | 2/20 | 0.35 |
| ▸ | TGM2 | P21980 | 2/20 | 0.35 |
| ▸ | IDO1 | P14902 | 2/20 | 0.35 |
| ▸ | TDO2 | P48775 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | CMA1 | P23946 | 1/20 | 0.32 |
| ▸ | AHR | P35869 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | CES2 | O00748 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | CASP1 | P29466 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29117338 | 0.77 | HTR2C (0.38) | CES1PDE7AHTR2CKMT2AMEN1 | |
| SCHEMBL27557599 | 0.72 | CES2 (0.40) | CES1KMT2AMEN1TP53CES2 | |
| SCHEMBL21433683 | 0.64 | — | — | |
| SCHEMBL9306599 | 0.64 | PGR (0.38) | CES1PDE7ATGM2HTR2CAHR | |
| SCHEMBL11883348 | 0.63 | ALDH1A1 (0.41) | ALDH1A1TP53TSHRCASP1SMN1; SMN2 | |
| Lithium Ion SCHEMBL984533 | 0.62 | MAPT (0.38) | TGM2IDO1ALDH1A1SMN1; SMN2 | |
| SCHEMBL24219873 | 0.61 | AHR (0.42) | TGM2IDO1TDO2HTR2CCMA1 | |
| SCHEMBL30748111 | 0.60 | HTR2C (0.38) | HTR2CALDH1A1TSHRSMN1; SMN2 | |
| SCHEMBL8629003 | 0.60 | NPC1 (0.49) | IDO1ALDH1A1TP53SMN1; SMN2 | |
| SCHEMBL16598094 | 0.59 | MAPT (0.64) | CES1HTR2CCMA1AHRTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120088746-A1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | PFIZER INC. (US) | 2012-04-12 | — | — | US | disclosed |
| EP-2024272-A2 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | Renovis, Inc. (US) | 2009-02-18 | — | — | EP | disclosed |
| WO-2007133637-A2 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | RENOVIS, INC. (US) | 2007-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088746-A1 | AMIDE DERIVATIVES AS ION-CHANNEL LIGANDS AND PHARMACEUTICAL COMPOSITIONS AND METHODS OF USING THE SAME | TRPV1, TRPA1, TRPV2 | CES1 2424/4885PDE7A 916/4885TGM2 2731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.